Clinical Impact of High Throughput Sequencing on Liquid Biopsy in Advanced Solid Cancer

Autor: Etienne Gouton, Nausicaa Malissen, Nicolas André, Arnaud Jeanson, Annick Pelletier, Albane Testot-Ferry, Caroline Gaudy-Marqueste, Laetitia Dahan, Emeline Tabouret, Thomas Chevalier, Laurent Greillier, Pascale Tomasini

Publikováno v: Current Oncology, Vol 29, Iss 3, Pp 1902-1918 (2022)

Background: Cancer therapies targeting actionable molecular alterations (AMA) have developed, but the clinical routine impact of high-throughput molecular profiling remains unclear. We present a monocentric experience of molecular profiling based on

Externí odkaz: https://doaj.org/article/f0a9f59028384b1fab0883316eb2f88f

532P Phase Ib study evaluating BI 836880 (VEGF/Ang2 nanobody) in combination with ezabenlimab (BI 754091; anti-PD-1 antibody) in patients with solid tumours

Autor: Jong Seok Lee, François Ghiringhelli, E. Ledin, David Berz, Mark Voskoboynik, Dai Woo Kim, Nicolas Girard, C. Mascaux, Martin Wermke, Jaafar Bennouna, Arnaud Jeanson, Piotr Serwatowski, Enriqueta Felip, Björn Hackanson, Thierry Lesimple, Victoria Chen, Girish Jayadeva, Jürgen Alt, Harald Timotheus Landsteiner, Michael C. Burger

Publikováno v: Annals of Oncology. 32:S597

Background: Combining anti-VEGF/Ang2 and anti-PD-1 therapy promotes an immunopermissive state, supportive of T-cell-mediated tumour cell destruction. This phase Ib study is assessing BI 836880 plus ezabenlimab in patients (pts) with advanced solid tu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a971eca64ae1d62a1ed2ab18c347d461
https://doi.org/10.1016/j.annonc.2021.08.1054

Therapeutic potential of trametinib to inhibit the mutagenesis by inactivating the protein kinase pathway in non-small cell lung cancer

Autor: Arnaud Boyer, Pascale Tomasini, Fabrice Barlesi, Arnaud Jeanson, Laurent Greillier

Publikováno v: Expert Review of Anticancer Therapy
Expert Review of Anticancer Therapy, 2019, 19 (1), pp.11-17. ⟨10.1080/14737140.2019.1554440⟩
Expert Review of Anticancer Therapy, Expert Reviews (formerly Future Drugs), 2019, 19 (1), pp.11-17. ⟨10.1080/14737140.2019.1554440⟩

International audience; Introduction:Mitogen-activated protein kinase (MAPK) pathway is known to be involved in the tumorigenesis of cancer cells including non-small cell lung cancer (NSCLC) and kinases involved in this pathway are frequently mutated

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04aa5c306f38c3bb075eda02646b64ad
https://hal.science/hal-02528498

Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer

Autor: Pascale Tomasini, Arnaud Jeanson, Fabrice Barlesi, M. Grangeon, N. Khobta, S. Chaleat, M. Souquet-Bressand, J. Bermudez, Y. Trigui, C. Mascaux, Marilyne Blanchon, Laurent Greillier, Mohamed Boucekine

Publikováno v: Clinical lung cancer. 20(3)

Immune checkpoint inhibitors (ICIs) are available for first- and further lines of treatment of patients with advanced non-small-cell lung cancer (NSCLC). These treatments are associated with adverse events called immune-related adverse events (IRAEs)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b13a145c5ec7fb0736fd2f4a994e171d
https://pubmed.ncbi.nlm.nih.gov/30442524

Interactions entre immunothérapie et radiothérapie dans le traitement du cancer bronchopulmonaire non à petites cellules, efficacité et tolérance

Autor: Mohamed Boucekine, S. Chaleat, Laurent Greillier, M. Grangeon, M. Souquet-Bressand, J. Bermudez, Arnaud Jeanson, S. Jourdan, Fabrice Barlesi, Y. Trigui, C. Mascaux, Pascale Tomasini

Publikováno v: Revue des Maladies Respiratoires. 35:A63-A64

Introduction L’immunotherapie a une place grandissante dans le traitement du cancer bronchique non a petites cellules (CBNPC). Des etudes precliniques suggerent une augmentation des effets secondaires, ainsi qu’une augmentation d’efficacite (ef

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::deba02140f8b400a3391ac73115fa3c3
https://doi.org/10.1016/j.rmr.2017.10.130